RecruitingNot ApplicableNCT07824583

A Study Evaluating a New Radiation Treatment Workflow (NGDS)

A ProSPEctivE Study of NGDS DMAT Workflow Feasibility

Sponsor

Varian, a Siemens Healthineers Company

Enrollment

20 participants

Start Date

Jul 31, 2026

Study Type

INTERVENTIONAL

Conditions

Pancreatic Cancer Lung Cancer (Diagnosis)Thoracic Cancers Abdominal Cancer Liver Cancer, Adult

Summary

The purpose of this research is to evaluate the "Next Generation Delivery System" (NGDS) and determine if this machine will be more efficient at delivering radiation in shorter treatment time and better patient tolerance, with less breath holding.

Eligibility

Min Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Next Generation Delivery System (NGDS) for people with abdominal cancer, liver cancer, adult, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 21 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICENext Generation Delivery System (NGDS)

Participant will receive a "mock" treatment on the NGDS machine. Participant will complete experience questionnaires.

Locations(2)

Siteman Cancer Center Washington University

St Louis, Missouri, United States

University Hospital Cleveland Medical Center

Cleveland, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07824583

Related Trials

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT0756215231 locations

GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

NCT07627191

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

NCT0727741316 locations

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

NCT073495379 locations

Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas

NCT042755573 locations